Similarly, in cancer patients, GM-CSF secreting allogeneic tumor vaccines have also been developed for clinical testing and evaluated in pancreatic cancer, breast cancer, and hormone-resistant prostate cancer [22-24]. The gene discussed is CSF2; the disease is neoplasm.